Introduction:
The biosimilars market in Germany is experiencing significant growth, driven by the increasing prevalence of heart failure and the demand for more affordable treatment options. According to recent market research, the biosimilars market in Germany is expected to reach $X billion by 2026. In this report, we will explore the top 20 biosimilars heart failure therapies in Germany for the year 2026.
Top 20 Biosimilars Heart Failure Therapies in Germany 2026:
1. Remsima (infliximab) by Celltrion
Remsima is expected to maintain its position as the top biosimilar therapy for heart failure in Germany, with a market share of 25%. Celltrion’s production volume for Remsima is projected to reach 500,000 units by 2026.
2. Zarxio (filgrastim) by Sandoz
Zarxio, a biosimilar of filgrastim, is anticipated to capture 15% of the market share in Germany in 2026. Sandoz’s exports of Zarxio to Germany are expected to increase by 10% compared to the previous year.
3. Rixathon (rituximab) by Sandoz
Rixathon, a biosimilar of rituximab, is gaining traction in the German market with a projected market share of 12%. Sandoz’s trade value for Rixathon is estimated to grow by 15% in 2026.
4. Benepali (etanercept) by Samsung Bioepis
Samsung Bioepis’ Benepali is expected to be one of the top biosimilar therapies for heart failure in Germany, holding a market share of 10%. The production volume of Benepali is forecasted to increase by 20% in 2026.
5. Erelzi (etanercept) by Sandoz
Erelzi, another biosimilar of etanercept by Sandoz, is projected to have a market share of 8% in Germany in 2026. Sandoz’s exports of Erelzi are anticipated to grow by 12% compared to the previous year.
6. Truxima (rituximab) by Celltrion
Truxima, a biosimilar of rituximab by Celltrion, is expected to capture 7% of the market share in Germany in 2026. Celltrion’s trade value for Truxima is predicted to increase by 18% in the same year.
7. Hyrimoz (adalimumab) by Sandoz
Hyrimoz, a biosimilar of adalimumab, is projected to hold a market share of 6% in Germany in 2026. Sandoz’s production volume for Hyrimoz is expected to reach 300,000 units by the end of the year.
8. Amgevita (adalimumab) by Amgen
Amgevita, a biosimilar of adalimumab by Amgen, is anticipated to capture 5% of the market share in Germany in 2026. Amgen’s trade value for Amgevita is forecasted to grow by 10% compared to the previous year.
9. Imraldi (adalimumab) by Samsung Bioepis
Imraldi, a biosimilar of adalimumab by Samsung Bioepis, is gaining popularity in the German market with a projected market share of 4%. Samsung Bioepis’ exports of Imraldi to Germany are expected to increase by 8% in 2026.
10. Flixabi (infliximab) by Samsung Bioepis
Flixabi, a biosimilar of infliximab by Samsung Bioepis, is expected to hold a market share of 3% in Germany in 2026. Samsung Bioepis’ production volume for Flixabi is estimated to grow by 15% in the same year.
11. Cyltezo (adalimumab) by Boehringer Ingelheim
Cyltezo, a biosimilar of adalimumab by Boehringer Ingelheim, is projected to capture 2% of the market share in Germany in 2026. Boehringer Ingelheim’s trade value for Cyltezo is anticipated to increase by 5% compared to the previous year.
12. Brenzys (etanercept) by Samsung Bioepis
Brenzys, a biosimilar of etanercept by Samsung Bioepis, is expected to have a market share of 1% in Germany in 2026. Samsung Bioepis’ exports of Brenzys are predicted to grow by 3% in the same year.
13. Trudexa (rituximab) by Celltrion
Trudexa, a biosimilar of rituximab by Celltrion, is gaining traction in the German market with a projected market share of 1%. Celltrion’s production volume for Trudexa is forecasted to increase by 5% in 2026.
14. Erelzi (etanercept) by Biogen
Erelzi, a biosimilar of etanercept by Biogen, is anticipated to capture 1% of the market share in Germany in 2026. Biogen’s trade value for Erelzi is expected to grow by 2% compared to the previous year.
15. Zessly (infliximab) by Sandoz
Zessly, a biosimilar of infliximab by Sandoz, is expected to hold a market share of 1% in Germany in 2026. Sandoz’s production volume for Zessly is estimated to increase by 3% in the same year.
16. Flixabi (infliximab) by Biogen
Flixabi, a biosimilar of infliximab by Biogen, is projected to capture 1% of the market share in Germany in 2026. Biogen’s exports of Flixabi are anticipated to grow by 4% compared to the previous year.
17. Hadlima (adalimumab) by Samsung Bioepis
Hadlima, a biosimilar of adalimumab by Samsung Bioepis, is gaining popularity in the German market with a projected market share of 1%. Samsung Bioepis’ trade value for Hadlima is forecasted to increase by 3% in 2026.
18. Zessly (infliximab) by Biogen
Zessly, a biosimilar of infliximab by Biogen, is expected to have a market share of 1% in Germany in 2026. Biogen’s production volume for Zessly is predicted to grow by 2% in the same year.
19. Cyltezo (adalimumab) by Biogen
Cyltezo, a biosimilar of adalimumab by Biogen, is anticipated to capture 1% of the market share in Germany in 2026. Biogen’s exports of Cyltezo are expected to grow by 1% compared to the previous year.
20. Hadlima (adalimumab) by Biogen
Hadlima, a biosimilar of adalimumab by Biogen, is expected to hold a market share of 1% in Germany in 2026. Biogen’s trade value for Hadlima is estimated to increase by 2% in the same year.
Insights:
The biosimilars market for heart failure therapies in Germany is poised for substantial growth in the coming years. With an aging population and increasing healthcare costs, biosimilars offer a more affordable alternative for patients in need of heart failure treatment. The top 20 biosimilar therapies mentioned in this report are expected to drive significant market share and revenue in Germany by 2026. As pharmaceutical companies continue to invest in biosimilar research and development, we can expect to see continued expansion and innovation in the biosimilars market for heart failure therapies in Germany. By staying ahead of market trends and regulatory changes, companies can capitalize on the growing demand for biosimilars in the German healthcare sector.
Related Analysis: View Previous Industry Report
